Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18304274rdf:typepubmed:Citationlld:pubmed
pubmed-article:18304274lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:18304274lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:18304274lifeskim:mentionsumls-concept:C0002260lld:lifeskim
pubmed-article:18304274lifeskim:mentionsumls-concept:C0025217lld:lifeskim
pubmed-article:18304274lifeskim:mentionsumls-concept:C0041228lld:lifeskim
pubmed-article:18304274lifeskim:mentionsumls-concept:C0003023lld:lifeskim
pubmed-article:18304274lifeskim:mentionsumls-concept:C1523987lld:lifeskim
pubmed-article:18304274lifeskim:mentionsumls-concept:C0238606lld:lifeskim
pubmed-article:18304274pubmed:issue2lld:pubmed
pubmed-article:18304274pubmed:dateCreated2008-2-28lld:pubmed
pubmed-article:18304274pubmed:abstractTextTo compare the cost-effectiveness of eflornithine and melarsoprol in the treatment of human African trypanosomiasis.lld:pubmed
pubmed-article:18304274pubmed:languageenglld:pubmed
pubmed-article:18304274pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18304274pubmed:citationSubsetIMlld:pubmed
pubmed-article:18304274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18304274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18304274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18304274pubmed:statusMEDLINElld:pubmed
pubmed-article:18304274pubmed:monthFeblld:pubmed
pubmed-article:18304274pubmed:issn1365-3156lld:pubmed
pubmed-article:18304274pubmed:authorpubmed-author:BoelaertMMlld:pubmed
pubmed-article:18304274pubmed:authorpubmed-author:JosenandoTTlld:pubmed
pubmed-article:18304274pubmed:authorpubmed-author:RobaysJJlld:pubmed
pubmed-article:18304274pubmed:authorpubmed-author:RaguenaudM...lld:pubmed
pubmed-article:18304274pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18304274pubmed:volume13lld:pubmed
pubmed-article:18304274pubmed:ownerNLMlld:pubmed
pubmed-article:18304274pubmed:authorsCompleteYlld:pubmed
pubmed-article:18304274pubmed:pagination265-71lld:pubmed
pubmed-article:18304274pubmed:meshHeadingpubmed-meshheading:18304274...lld:pubmed
pubmed-article:18304274pubmed:meshHeadingpubmed-meshheading:18304274...lld:pubmed
pubmed-article:18304274pubmed:meshHeadingpubmed-meshheading:18304274...lld:pubmed
pubmed-article:18304274pubmed:meshHeadingpubmed-meshheading:18304274...lld:pubmed
pubmed-article:18304274pubmed:meshHeadingpubmed-meshheading:18304274...lld:pubmed
pubmed-article:18304274pubmed:meshHeadingpubmed-meshheading:18304274...lld:pubmed
pubmed-article:18304274pubmed:meshHeadingpubmed-meshheading:18304274...lld:pubmed
pubmed-article:18304274pubmed:meshHeadingpubmed-meshheading:18304274...lld:pubmed
pubmed-article:18304274pubmed:meshHeadingpubmed-meshheading:18304274...lld:pubmed
pubmed-article:18304274pubmed:meshHeadingpubmed-meshheading:18304274...lld:pubmed
pubmed-article:18304274pubmed:year2008lld:pubmed
pubmed-article:18304274pubmed:articleTitleEflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola.lld:pubmed
pubmed-article:18304274pubmed:affiliationInstitute of Tropical Medicine, Antwerp, Belgium.lld:pubmed
pubmed-article:18304274pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18304274pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18304274lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18304274lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18304274lld:pubmed